Truqap® Tablets for HR+ HER2- Breast Cancer

Truqap is a targeted oral therapy used with fulvestrant for select HR+ HER2- advanced breast cancer. We support access with US delivery from Canada, helping patients compare options without insurance. This guide explains how it works, who it may suit, and safe use basics.

What Truqap Is and How It Works

Truqap® (capivasertib) is an AKT pathway inhibitor taken by mouth. It is approved with fulvestrant for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer that has one or more PIK3CA, AKT1, or PTEN alterations after progression on endocrine therapy. See background on fulvestrant in our overview, Fulvestrant Injection. For condition-specific context, visit Breast Cancer.

Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing.

This medicine inhibits AKT, a key node in the PI3K/AKT pathway that drives tumor cell survival and growth. By dampening this signal in tumors with relevant alterations, the treatment may help slow disease progression when used with endocrine therapy. Clinical use follows the official label and your clinician’s direction.

Who It’s For

This treatment is for adults with HR-positive, HER2-negative advanced or metastatic breast cancer. Tumors should have a qualifying PIK3CA, AKT1, or PTEN alteration confirmed by an approved test before starting. It is used with intramuscular fulvestrant. Learn more about oncology options within Cancer.

People with a history of severe hypersensitivity to any component should not take it. Those who are pregnant, trying to become pregnant, or breastfeeding should avoid therapy. Because it can raise blood sugar, patients with diabetes require close monitoring and coordination with their clinician. Discuss your other conditions and medicines before starting.

Dosage and Usage

The typical schedule is taken in repeating weekly cycles: doses twice daily for four days, followed by three days off. Your prescriber aligns this with fulvestrant, which is given on day 1, day 15, and then every 28 days. When dose details are uncertain, follow the official label and your clinician’s advice.

Swallow tablets whole with water. Take with or without food at about the same times each day. Do not crush, split, or chew. If vomiting occurs after a dose, do not take an extra tablet; resume the next scheduled dose. Avoid grapefruit or grapefruit juice because of interaction potential.

Fulvestrant is commonly part of the regimen; you can review practical information alongside endocrine partners in Exemestane Tablets and Anastrozole Uses.

Your clinician may check glucose, liver enzymes, and skin regularly during treatment. Report new or worsening symptoms promptly. Only a prescriber can decide if temporary interruption or dose adjustments are appropriate.

Strengths and Forms

Tablets are supplied in multiple strengths, commonly 160 mg and 200 mg, to support labeled dosing. Packaging and exact presentations can vary by manufacturer lot and country. Availability may change over time based on supply and regulatory status.

Missed Dose and Timing

If you miss a dose, take it as soon as you remember unless it is close to the time for the next dose. If it is near the next scheduled time, skip the missed dose and resume your usual schedule. Do not take two doses at once to make up for a missed tablet. Keep the four-days-on and three-days-off rhythm consistent unless your prescriber tells you otherwise.

Storage and Travel Basics

Keep tablets in the original child-resistant container with the label intact. Store at room temperature, away from moisture and direct heat. Do not place tablets in pill organizers unless your clinician says it is safe for your setting. The phrase Truqap tablet bottle refers to the labeled container you receive from the pharmacy.

For travel, carry your medication in hand luggage with the prescription label. Pack enough for the trip plus extra in case of delays. Keep a simple list of your medicines and doses. If crossing time zones, maintain approximate dosing intervals and ask your clinician for a written plan when needed. Dispose of unused or expired tablets according to local guidance; do not flush.

Benefits

This targeted therapy focuses on a defined cancer pathway that is often active in endocrine-resistant disease. Used with fulvestrant, it may help delay disease progression in patients whose tumors harbor qualifying alterations. Oral dosing and a structured four-days-on schedule can fit varied routines. Many effects can be managed with supportive care and monitoring, guided by your clinician.

Side Effects and Safety

• Diarrhea
• Skin rash or redness
• Mouth sores
• High blood sugar
• Nausea or vomiting
• Decreased appetite
• Fatigue or weakness

Serious or uncommon risks can include severe hyperglycemia, significant skin reactions, dehydration from diarrhea, and liver enzyme elevations. Rare events may require interruption or discontinuation. The medicine can harm an unborn baby. Use effective contraception during treatment and for the label-specified period after the last dose. Seek urgent help for severe rash, persistent vomiting, confusion, or signs of high blood sugar such as increased thirst and frequent urination.

Drug Interactions and Cautions

Strong CYP3A inhibitors (for example, clarithromycin, itraconazole) can raise drug levels. Strong CYP3A inducers (such as rifampin, carbamazepine, St. John’s wort) can lower exposure. Avoid grapefruit products. Tell your clinician about all prescription, over-the-counter, and herbal products. People using medicines that affect blood sugar may need closer monitoring because this therapy can increase glucose. Do not change doses of any medicine without medical guidance.

What to Expect Over Time

Most patients continue therapy as long as it controls disease and side effects remain manageable. Blood tests and skin checks often occur early, then at regular intervals. Diarrhea or rash may appear during the first cycles and can often be managed with supportive care. Imaging and clinical reviews assess response. Adherence to the four-days-on schedule is important for steady exposure. For tips on managing endocrine partner effects, see Exemestane Side Effects.

Compare With Alternatives

Other systemic options for HR+ HER2- advanced breast cancer include CDK4/6 inhibitors and chemotherapy. For example, Verzenio is an oral CDK4/6 inhibitor used with endocrine therapy in appropriate patients. When targeted options are not suitable, agents like Doxorubicin may be considered based on prior treatment and clinical goals. Endocrine partners remain central; see Fulvestrant Injection for details.

Pricing and Access

We present current options so you can review Capivasertib price and compare supply choices. Patients often look for Truqap Canadian pricing alongside US shipping from Canada, which can help with budget planning. Check live availability, view pricing details, and see dispensing information before you start an order. For site discounts and seasonal offers, visit Promotions. Our checkout is encrypted for your security.

Savings CTA: Explore potential savings when you coordinate insurance benefits with cash-pay options and assistance programs your care team recommends. Pricing CTA: Review current pricing and supply sizes before you add to cart so your clinician can align quantity with your dosing schedule. You can also browse origin information at Canada.

Availability and Substitutions

Supply can vary by strength and package size. If a specific presentation is unavailable, a prescriber may recommend an alternative or an adjusted plan. Some patients search for Capivasertib tablets online to compare supply sources; ensure any outlet requires a valid prescription and dispenses from licensed pharmacies.

Patient Suitability and Cost-Saving Tips

Candidates often include adults with HR+ HER2- advanced disease and a confirmed PIK3CA, AKT1, or PTEN alteration. People with poorly controlled diabetes, active infections, or significant liver disease may need extra caution. Those who cannot swallow tablets whole are not good candidates.

• Gene testing: confirm tumor alterations before starting
• Plan labs: schedule glucose and liver checks
• Multi-month fills: reduce refill gaps and travel stress
• Reminders: set calendar alerts for four-on, three-off rhythm
• Budget planning: discuss options to pay cash for Truqap if needed
• Care coordination: share all medicines with your clinician

Questions to Ask Your Clinician

• Is my tumor confirmed to have a PIK3CA, AKT1, or PTEN alteration?
• How will we coordinate fulvestrant injections with my tablet schedule?
• What signs of high blood sugar or dehydration should I watch for?
• Which medicines, supplements, or foods should I avoid?
• How often will labs and imaging be checked?
• What is the plan if I miss doses or experience severe diarrhea?
• Are there financial assistance or scheduling options that fit my needs?

Authoritative Sources

FDA Prescribing Information

Manufacturer Site

Health Canada Drug Product Database

Ready to start? Place your order with prompt, express shipping. Ships from Canada to US. Prescription required; temperature-controlled handling when required.

Disclaimer: This page summarizes approved information and is not medical advice. Always follow your clinician’s guidance and the official label.